NCT04879316

Energy for Lymphocytes

Analysis of Nutritional Biomarkers to Predict the Efficacy of Immunotherapy by Anti-PD/PDL1 Checkpoints Inhibitors in Metastatic Non-small Cell Lung Cancer Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 144 (actual)
• Sponsor: Hôpital Cochin · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

CERTIM is a cohort created in July 2015 to set up a multidisciplinary follow-up of cancer patients treated with immune checkpoint inhibitors. From the CERTIM cohort, we conducted a longitudinal, prospective, observational study (ELY) in two tertiary university centers (Cochin hospital and European Georges Pompidou Hospital), which included patients between August 2016 and October 2019 and ended follow-up in April 2020. Patients were treated with nivolumab, at a dose of 3 mg/kg every 2 weeks, or pembrolizumab, at a dose of 2mg/kg every 3 weeks. The investigators report findings from an evaluation of rest energy expenditure (REE) assessed using indirect calorimetry in the outpatient setting before treatment with checkpoints inhibitors.

Conditions

• Non-small Cell Lung Cancer
• Progression, Disease

Interventions

Type	Name	Description
OTHER	Resting Energy Expenditure measurement	Resting Energy Expenditure measurement using indirect calorimetry

Timeline

• Start date: 2016-08-01
• Primary completion: 2019-10-01
• Completion: 2020-04-30
• First posted: 2021-05-10
• Last updated: 2021-05-12

Locations

1 site across 1 country: France